Metformin in non-alcoholic fatty liver disease: A systematic review and meta‑analysis

  • Authors:
    • Yan Li
    • Lei Liu
    • Bin Wang
    • Jun Wang
    • Dongfeng Chen
  • View Affiliations

  • Published online on: October 9, 2012     https://doi.org/10.3892/br.2012.18
  • Pages: 57-64
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non-alcoholic fatty liver disease (NAFLD) related to insulin resistance (IR) is a growing global health concern. Recent studies have indicated that metformin could improve IR and may be beneficial in the treatment of NAFLD. This study aimed to assess the beneficial or harmful effects of metformin in NAFLD. We searched Medline and four other databases during April 2012. Selection criteria were randomized clinical trials comparing metformin with placebo or other interventions for treating NAFLD patients. The primary outcome was histological response. The secondary outcomes included alanine aminotransferase (ALT), aspartate aminotransferase (AST), homeostasis model assessment of IR (HOMA‑IR), body mass index (BMI) and adverse events. Dichotomous data were reported as odds ratio (OR), while continuous data were calculated as the mean difference (MD), both with 95% confidence intervals (CI). Random and fixed effects meta-analyses were performed. Nine studies were included, involving 417 participants, and conducted for a time period ranging from 4 to 12 months. In the treated participants, improvements were observed in ALT (MD, -8.12 U/l; P=0.03), AST (MD, -4.52 U/l; P=0.04), HOMA‑IR (MD, -0.61; P=0.005) and BMI (MD, -0.82 kg/m2; P=0.04), but not in histological response: steatosis (P=0.66), inflammation (P=0.91), hepatocellular ballooning (P=0.25) and fibrosis (P=0.90). Sub‑analysis of non‑alcoholic fatty steatohepatitis showed that metformin failed to improve any pooled outcome. Adverse events were poorly reported. Current information indicates that metformin improves liver function, HOMA‑IR and BMI to some extent, but not histological response in NAFLD patients. This finding could serve as a stimulus for future studies investigating issues such as dose‑responsiveness, safety and patient tolerance to metformin therapy.

References

1. 

Cohen JC, Horton JD and Hobbs HH: Human fatty liver disease: old questions and new insights. Science. 332:1519–1523. 2011. View Article : Google Scholar : PubMed/NCBI

2. 

Chalasani N, Younossi Z, Lavine JE, et al: The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 142:1592–1609. 2012. View Article : Google Scholar

3. 

Wieckowska A, McCullough AJ and Feldstein AE: Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 46:582–589. 2007. View Article : Google Scholar : PubMed/NCBI

4. 

Liou I and Kowdley KV: Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 40:S11–S16. 2006.

5. 

Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43:S99–S112. 2006. View Article : Google Scholar : PubMed/NCBI

6. 

Alberti KG, Zimmet P and Shaw J; IDF Epidemiology Task Force Consensus Group: The metabolic syndrome - a new worldwide definition. Lancet. 366:1059–1062. 2005. View Article : Google Scholar : PubMed/NCBI

7. 

Targher G, Day CP and Bonora E: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 363:1341–1350. 2010. View Article : Google Scholar : PubMed/NCBI

8. 

Dunn W, Xu R, Wingard DL, et al: Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 103:2263–2271. 2008. View Article : Google Scholar : PubMed/NCBI

9. 

Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI

10. 

McCullough AJ: Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 34:255–262. 2002. View Article : Google Scholar : PubMed/NCBI

11. 

Owen MR, Doran E and Halestrap AP: Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 348:607–614. 2000. View Article : Google Scholar : PubMed/NCBI

12. 

Zhou G, Myers R, Li Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI

13. 

Browning JD and Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 114:147–152. 2004. View Article : Google Scholar : PubMed/NCBI

14. 

Moseley RH: Therapy for nonalcoholic fatty liver disease. J Clin Gastroenterol. 42:332–335. 2008. View Article : Google Scholar : PubMed/NCBI

15. 

Loomba R, Lutchman G, Kleiner DE, et al: Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 29:172–182. 2009. View Article : Google Scholar : PubMed/NCBI

16. 

Lam B and Younossi ZM: Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 3:121–137. 2010. View Article : Google Scholar : PubMed/NCBI

17. 

Rakoski MO, Singal AG, Rogers MA and Conjeevaram H: Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 32:1211–1221. 2010. View Article : Google Scholar : PubMed/NCBI

18. 

Mazza A, Fruci B, Garinis GA, et al: The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012:7164042012. View Article : Google Scholar : PubMed/NCBI

19. 

Higgins PTJ and Green S: Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.6. The Cochrane Collaboration, 2011 (Available at: www.cochrane-handbook.orgurisimplewww.cochrane-handbook.org). Accessed April 2, 2012.

20. 

Haukeland JW, Konopski Z, Eggesbo HB, et al: Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 44:853–860. 2009. View Article : Google Scholar : PubMed/NCBI

21. 

Shields WW, Thompson KE, Grice GA, et al: The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol. 2:157–163. 2009. View Article : Google Scholar

22. 

Sofer E, Boaz M, Matas Z, et al: Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism. 60:1278–1284. 2011. View Article : Google Scholar

23. 

Bugianesi E, Gentilcore E, Manini R, et al: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 100:1082–1090. 2005. View Article : Google Scholar : PubMed/NCBI

24. 

Garinis GA, Fruci B, Mazza A, et al: Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond). 34:1255–1264. 2010. View Article : Google Scholar : PubMed/NCBI

25. 

Uygun A, Kadayifci A, Isik AT, et al: Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 19:537–544. 2004. View Article : Google Scholar : PubMed/NCBI

26. 

Akyüz F, Demir K, Ozdil S, et al: The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig Dis Sci. 52:2359–2367. 2007.PubMed/NCBI

27. 

Idilman R, Mizrak D, Corapcioglu D, et al: Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 28:200–208. 2008. View Article : Google Scholar

28. 

Nar A and Gedik O: The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol. 46:113–118. 2009. View Article : Google Scholar : PubMed/NCBI

29. 

Musso G, Gambino R, Cassader M, et al: A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 52:79–104. 2010. View Article : Google Scholar : PubMed/NCBI

30. 

Musso G, Cassader M, Rosina F and Gambino R: Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 55:885–904. 2012. View Article : Google Scholar

31. 

Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al: Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. World J Gastroenterol. 12:7826–7831. 2006.PubMed/NCBI

32. 

Adams LA and Angulo P: Treatment of non-alcoholic fatty liver disease. Postgrad Med J. 82:315–322. 2006. View Article : Google Scholar : PubMed/NCBI

33. 

Mofrad P, Contos MJ, Haque M, et al: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 37:1286–1292. 2003. View Article : Google Scholar : PubMed/NCBI

34. 

Adams LA, Sanderson S, Lindor KD, et al: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 42:132–138. 2005. View Article : Google Scholar : PubMed/NCBI

35. 

Orlando R, Azzalini L, Orando S, et al: Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 1:CD0051602007.

36. 

Filik L: Role of type 2 diabetes mellitus in nonalcoholic fatty liver disease. Eur J Clin Invest. 41:1367–1368. 2011. View Article : Google Scholar : PubMed/NCBI

37. 

Bonapace S, Perseghin G, Molon G, et al: Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 35:389–395. 2012. View Article : Google Scholar : PubMed/NCBI

38. 

Stumvoll M, Nurjhan N, Perriello G, et al: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 333:550–554. 1995. View Article : Google Scholar : PubMed/NCBI

39. 

Hemmingsen B, Christensen LL, Wetterslev J, et al: Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ. 344:1771–1779. 2012. View Article : Google Scholar

40. 

Nadeau KJ, Ehlers LB, Zeitler PS, et al: Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes. 10:5–13. 2009. View Article : Google Scholar : PubMed/NCBI

41. 

Lavine JE, Schwimmer JB, Van Natta ML, et al: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 305:1659–1668. 2011. View Article : Google Scholar : PubMed/NCBI

42. 

Lavine JE, Schwimmer JB, Molleston JP, et al: Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials. 31:62–70. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January 2013
Volume 1 Issue 1

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, Y., Liu, L., Wang, B., Wang, J., & Chen, D. (2013). Metformin in non-alcoholic fatty liver disease: A systematic review and meta‑analysis. Biomedical Reports, 1, 57-64. https://doi.org/10.3892/br.2012.18
MLA
Li, Y., Liu, L., Wang, B., Wang, J., Chen, D."Metformin in non-alcoholic fatty liver disease: A systematic review and meta‑analysis". Biomedical Reports 1.1 (2013): 57-64.
Chicago
Li, Y., Liu, L., Wang, B., Wang, J., Chen, D."Metformin in non-alcoholic fatty liver disease: A systematic review and meta‑analysis". Biomedical Reports 1, no. 1 (2013): 57-64. https://doi.org/10.3892/br.2012.18